Paltusotine can alleviate symptoms of carcinoid syndrome in patients with neuroendocrine tumors, a phase 2 study suggests.

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.